Pharmacological treatment of cannabis-related disorders: A narrative review

Current Pharmaceutical Design

Volumn 22, Issue , 2016, Pages

  Gorelick, David A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Cannabis use disorder; Comorbidity; Intoxication; Marijuana; Pharmacology; Treatment; Withdrawal

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ACETYLCYSTEINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; DOPAMINE; DRONABINOL; GABAPENTIN; GLUTAMIC ACID; NEUROLEPTIC AGENT; NORADRENALIN; PROPRANOLOL; SEROTONIN; AMINE; CANNABIS; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; ANTIDOTE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST;

ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; CANNABIS USE; CANNABIS-INDUCED PSYCHOSIS; COMORBIDITY; DATA BASE; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INTOXICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; WITHDRAWAL SYNDROME; ANIMAL; CANNABIS USE DISORDER; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG INDUCED DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC);

ACETYLCYSTEINE; AMINES; ANIMALS; CANNABIS; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MARIJUANA ABUSE;

EID: 85010703492     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160822150822     Document Type: Review

References (94)

1. United Nations Office on Drugs and Crime. World Drug Report 2015. Vienna, Austria: 2015 Contract No.: United Nations publication, Sales No. E.15.XI.6.
2. Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PloS one 2013; 8(10): e76635.
3. Goldstein RB, Chou SP, Smith SM, et al. Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. J studies on alcohol and drugs 2015; 76(3): 378-88.
4. Center for Behavioral Health Statistics and Quality 2013 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.
5. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA psychiatry 2015; 72(12): 1235-42.
6. Moss HB, Chen CM, Yi HY. Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. J Studies Alcohol Drugs 2012; 73(5): 820-8.
7. Perkonigg A, Goodwin RD, Fiedler A, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction (Abingdon, England) 2008; 103(3): 439-49; discussion 50-1.
8. Calabria B, Degenhardt L, Briegleb C, et al. Systematic review of prospective studies investigating “remission” from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 2010; 35(8): 741-9.
9. Cunningham JA. Remissions from drug dependence: is treatment a prerequisite? Drug Alcohol Depend 2000; 59(3): 211-3.
10. Hughes JR, Naud S, Budney AJ, Fingar JR, Callas PW. Attempts to Stop or Reduce Daily Cannabis Use: An Intensive Natural History Study. Psychol Addict Behav 2016.
11. Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. Rockville, MD: 2015 HHS Publication No. (SMA) 15-4934.
12. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016; 5: CD005336.
13. Barnett E, Sussman S, Smith C, Rohrbach LA, Spruijt-Metz D. Motivational Interviewing for adolescent substance use: a review of the literature. Addict Behav 2012; 37(12): 1325-34.
14. Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA. Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof 2015; 38(1): 94-114.
15. Cooper K, Chatters R, Kaltenthaler E, Wong R. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health technology assessment (Winchester, England) 2015; 19(56): 1-130.
16. Tait RJ, Spijkerman R, Riper H. Internet and computer based interventions for cannabis use: a meta-analysis. Drug Alcohol Depend 2013; 133(2): 295-304.
17. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des 2011; 17(14): 1351-8.
18. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014; 12: CD008940.
19. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatric Clin North Am 2012; 35(2): 309-26.
20. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: Current science and future outlook. Pharmacotherapy 2016. Epub 2016/03/31.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013 2013.
22. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Ann Rev Psychol 2013; 64: 21-47.
23. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008; 154(2): 369-83.
24. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers Plant Sci 2016; 7: 19.
25. Huestis MA, Boyd SJ, Heishman SJ, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 2007; 194(4): 505-15.
26. Klumpers LE, Beumer TL, van Hasselt JG, et al. Novel Delta(9)-tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012; 74(1): 42-53. Epub 2012/06/12.
27. Crippa JA, Derenusson GN, Chagas MH, et al. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduc J 2012; 9(1): 7.
28. Bui QM, Simpson S, Nordstrom K. Psychiatric and medical management of marijuana intoxication in the emergency department. Western J Emergency Med 2015; 16(3): 414-7.
29. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology 2009; 205(1): 171-4.
30. Sulkowski A, Vachon L, Rich ES, Jr. Propranolol effects on acute marihuana intoxication in man. Psychopharmacology 1977; 52(1): 47-53.
31. Rubio F, Quintero S, Hernandez A, et al. Flumazenil for coma reversal in children after cannabis. Lancet 1993; 341(8851): 1028-9.
32. Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14(3): 177-80.
33. Berk SBF, Nur M. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double blind randomized controlled trial. Int J Psychiatry Clin Practice 2000; 4(2): 139-42.
34. Allsop DJ, Copeland J, Norberg MM, et al. Quantifying the clinical significance of cannabis withdrawal. PloS one 2012; 7(9): e44864.
35. Levin KH, Copersino ML, Heishman SJ, et al. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 2010; 111(1-2): 120-7.
36. D’Souza DC, Cortes-Briones JA, Ranganathan M, et al. Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging 2016; 1(1): 60-7.
37. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007; 86(1): 22-9.
38. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011; 116(1-3): 142-50.
39. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA psychiatry 2014; 71(3): 281-91.
40. Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012; 37(7): 1689-98.
41. Johnston J, Lintzeris N, Allsop DJ, et al. Lithium carbonate in the management of cannabis withdrawal: a randomized placebocontrolled trial in an inpatient setting. Psychopharmacology 2014; 231(24): 4623-36.
42. Allsop DJ, Bartlett DJ, Johnston J, et al. The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. J Clin Sleep Med: JCSM 2015; 11(10): 1153-62.
43. Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend 2011; 117(1): 38-44.
44. Arendt M, Rosenberg R, Foldager L, Sher L, Munk-Jorgensen P. Withdrawal symptoms do not predict relapse among subjects treated for cannabis dependence. Am J Addict 2007; 16(6): 461-7.
45. Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR. Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 2015; 232(15): 2723-9.
46. Sami MB, Rabiner EA, Bhattacharyya S. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. Eur Neuropsychopharmacol 2015; 25(8): 1201-24.
47. Kuepper R, Ceccarini J, Lataster J, et al. Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PloS one 2013; 8(7): e70378.
48. Gage SH, Hickman M, Zammit S. Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biol Psychiatry 2016; 79(7): 549-56.
49. Martins SS, Gorelick DA. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend 2011; 119(1-2): 28-36.
50. Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009; 56 Suppl 1: 235-43.
51. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 2016; 17(5): 293-306.
52. Fitzgerald ML, Shobin E, Pickel VM. Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 38(1): 21-9.
53. Carvalho AF, Van Bockstaele EJ. Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38(1): 59-67.
54. Fisar Z. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38(1): 68-77.
55. Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neurosci Biobehav Rev 2016; 64: 359-81.
56. Prescot AP, Renshaw PF, Yurgelun-Todd DA. gamma-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend 2013; 129(3): 232-9.
57. Theunissen EL, Heckman P, de Sousa Fernandes Perna EB, et al. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology 2015; 232(2): 343-53.
58. Levin FR, Mariani JJ, Pavlicova M, et al. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2016; 159: 53-60.
59. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2008; 197(1): 157-68.
60. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabisdependent adolescents. Am J Psychiatry 2012; 169(8): 805-12.
61. Weinstein AM, Miller H, Bluvstein I, et al. Treatment of cannabis dependence using escitalopram in combination with cognitivebehavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse 2014; 40(1): 16-22.
62. McRae-Clark AL, Baker NL, Gray KM, Killeen T, Hartwell KJ, Simonian SJ. Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict 2016; 25(1): 69-75.
63. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009; 18(1): 53-64.
64. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebocontrolled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009; 105(1-2): 132-8.
65. McRae-Clark AL, Baker NL, Gray KM, et al. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend 2015; 156: 29-37.
66. Miranda R, Jr., Treloar H, Blanchard A, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addic Biol 2016. Epub 2016/01/12.
67. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004; 13(1): 21-32.
68. Magruder KMOB, Miller S, Tilley BC. Retention of underrepresented minorities in drug abuse treatment studies. Clin Trials 2009; 6: 252-60.
69. McRae-Clark AL, Baker NL, Sonne SC, DeVane CL, Wagner A, Norton J. Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence. J Substance Abuse Treatment 2015; 57: 70-4.
70. Herron AJ, Mariani JJ, Pavlicova M, et al. Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement. Drug Alcohol Depend 2013; 128(1-2): 77-82.
71. Peters EN, Nich C, Carroll KM. Primary outcomes in two randomized controlled trials of treatments for cannabis use disorders. Drug Alcohol Depend 2011; 118(2-3): 408-16.
72. Ghitza UE, Epstein DH, Preston KL. Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav 2007; 32(5): 938-49.
73. Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Therapeutic drug monitoring 2006; 28(2): 155-63.
74. Okuda M, Hasin DS, Olfson M, et al. Generalizability of clinical trials for cannabis dependence to community samples. Drug Alcohol Depend 2010; 111(1-2): 177-81.
75. Frewen AR, Baillie AJ, Montebello ME. Are cannabis users who participate in a randomized clinical trial different from other treatment seekers? J Substance Abuse Treatment 2009; 36(3): 339-44.
76. Balter RE, Cooper ZD, Haney M. Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. Curr Addic Rep 2014; 1(2): 137-43.
77. Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther 2015; 97(6): 571-4.
78. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology 2015; 40(11): 2489-98.
79. Herrmann ES, Cooper ZD, Bedi G, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology 2016. Epub 2016/04/18.
80. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol 2009; 23(1): 84-93.
81. Cooper ZD, Haney M. Opioid antagonism enhances marijuana’s effects in heavy marijuana smokers. Psychopharmacology 2010; 211(2): 141-8.
82. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 2012; 37(1): 11-24.
83. Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry 2010; 71(3): 247-54.
84. Wilson RP, Bhattacharyya S. Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review. J Psychopharmacol 2016; 30(2): 99-111.
85. McClure EA, Baker NL, Gray KM. Cigarette smoking during an Nacetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse 2014; 40(4): 285-91.
86. Cornelius JR, Bukstein OG, Douaihy AB, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend 2010; 112(1-2): 39-45.
87. Cornelius JR, Salloum IM, Haskett RF, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 1999; 24(1): 111-4.
88. Levin FR, Mariani J, Brooks DJ, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for cooccurring cannabis dependence and depressive disorders. Addiction (Abingdon, England) 2013; 108(6): 1084-94.
89. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010; 19(6): 481-9.
90. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 2007; 16(4): 260-8.
91. van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry 2008; 53(6): 400-5.
92. Sevy S, Robinson DG, Sunday S, et al. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res 2011; 188(3): 310-4.
93. Schnell T, Koethe D, Krasnianski A, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 2014; 23(3): 308-12.
94. Brunette MF, Dawson R, O’Keefe CD, et al. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagnosis 2011; 7(1-2): 50-63.